Miao Xu

机构：Nankai University, National Medical Products Administration, National Health and Family Planning Commission, China Banking Regulatory Commission, Guangzhou Experimental Station, Changsha Central Hospital, National Institutes for Food and Drug Control, Changsha Hospital for Maternal and Child Health Care, National Center for Advancing Translational Sciences, The Eighth Hospital of Xi'an · ORCID：0000-0002-6472-293X

发表论文 100 篇 · 总被引 7311 次 · h-index 32

代表论文

• Research Advances on the Stability of mRNA Vaccines (2023 · Viruses · 被引 159)
• Design Strategies for Novel Lipid Nanoparticle for mRNA Vaccine and Therapeutics: Current Understandings and Future Perspectives (2025 · MedComm · 被引 37)
• Therapeutic Effect of Subunit Vaccine AEC/BC02 on Mycobacterium tuberculosis Post-Chemotherapy Relapse Using a Latent Infection Murine Model (2022 · Vaccines · 被引 29)
• Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays (2023 · Expert Review of Vaccines · 被引 17)
• Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines (2024 · Expert Review of Vaccines · 被引 16)
• Amplifying mRNA vaccines: potential versatile magicians for oncotherapy (2023 · Frontiers in Immunology · 被引 13)